UK Markets closed

Evotec SE (EVOTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
43.520.00 (0.00%)
At close: 12:51PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.52
Open43.52
BidN/A x N/A
AskN/A x N/A
Day's range43.52 - 43.52
52-week range26.26 - 44.00
Volume20,154
Avg. volume596
Market cap7.109B
Beta (5Y monthly)0.84
PE ratio (TTM)906.63
EPS (TTM)0.05
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    EVOTEC SE REPORTS RESULTS FOR THE FIRST QUARTER 2021 AND PROVIDES CORPORATE UPDATE

    DGAP-News: Evotec SE / Key word(s): Quarter Results/Quarterly / Interim Statement11.05.2021 / 07:00 The issuer is solely responsible for the content of this announcement. SUCCESSFUL START TO 2021 WITH STRONG STRATEGIC POSITION AND LONG-TERM STRATEGY: ACTION PLAN 2025 "THE DATA-DRIVEN R&D AUTOBAHN TO CURES" GOOD PROGRESS WITHIN PRODUCT DEVELOPMENT PARTNERSHIPS AND CO-OWNED PORTFOLIO CONTINUED POSITIVE FINANCIAL PERFORMANCE; NO MATERIAL IMPACT THROUGH COVID-19 PANDEMICHamburg, Germany, 11 May 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the financial results and corporate updates for the first quarter 2021.HIGHLIGHTSRECORD LIKE-FOR-LIKE GROWTH OF BASE BUSINESS, STRONG BALANCE SHEET SUPPORTS ACCELERATING GROWTH Group revenues from contracts with customers increased by 11% to € 133.1 m (Q1 2020: € 119.4 m); Base business growth of 28%, adjusted for the end of the Sanofi payment (since April 2020) and unfavourable fx effects EVT Execute revenue growth of 16% (11% adjusted for material recharges) to € 136.9 m (Q1 2020: € 118.2 m), EVT Innovate revenues up 21% (20% adjusted for material recharges) to € 28.2 m (Q1 2020: € 23.3 m) Just - Evotec Biologics grew by more than 60% to € 9.7 m (Q1 2020: € 5.9 m) Like-for-like growth of adjusted Group EBITDA of 16%, despite higher R&D expenses; adjusted Group EBITDA of € 21.1 m (Q1 2020: € 30.0 m) affected by the anticipated end of the Sanofi payment (since April 2020) and unfavourable fx effects Increased expenses for unpartnered R&D of € 14.9 m (Q1 2020: € 11.4 m) according to strategy Strong balance sheet with comfortable net debt position of € 56 m (equivalent to 0.6x EBITDA) provides significant room for financing further growth; non-operating result benefits from fair value adjustment of the investment in Exscientia Ltd.POSITIVE DEVELOPMENT WITH SEVERAL NEW AND EXPANDED PARTNERSHIPS; JUST - EVOTEC BIOLOGICS FURTHER GAINING MOMENTUM Multiple new and extended partnerships and alliances (e.g. with Annexon, Chinook Therapeutics, Related Sciences, Takeda, The Mark Foundation, ...) New development collaborations and INDiGO contracts signed (e.g. Riboscience, Step Pharma, ...) New iPSC- multi-year partnership with the Medical Center Hamburg Eppendorf ("UKE") Bristol Myers Squibb extend partnership in the field of targeted protein degradation Just - Evotec Biologics continuing on its success course: progress of the first J.POD(R) facility in Redmond on schedule; construction of first European "J.POD(R) 2 EU" expected to start in H2 2021 Partnership on oncology project EVT801 with Kazia Therapeutics (after period-end) New BRIDGEs ("beLAB2122" and "beLAB1407" (after period-end)) Projects entering into clinical phases (EVT894 (Chik-V); Immuno-oncology project A2a receptor antagonist (Exscientia))CORPORATE HIGHLIGHTS Implementation of next long-term strategic framework Action Plan 2025 "The data-driven R&D Autobahn to Cures" Chairman of the Supervisory Board of Evotec to retire from office effective as of the end of the Annual General Meeting on 15 June 2021 (after period-end)GUIDANCE FOR FULL-YEAR 2021 CONFIRMED Business outlook for 2021 confirmed and mid-term targets given for the first time Group revenues expected to be in a range of € 550 - 570 m (€ 565 - 585 m at constant exchange rates) (2020: € 500.9 m) Adjusted Group EBITDA expected to be in the range of € 105 - 120 m (€ 115 - 130 m at constant exchange rates) (2020: € 106.6 m) Unpartnered research and development expenses expected to be in a range of € 50 - 60 m (2020: € 46.4 m)INTRODUCTION OF MID-TERM GOALS ALIGNED WITH ACTION PLAN 2025 Introduction of mid-term goals until 2025 at Capital Markets Day on 20 April 2021, targeting revenues growth to > € 1,000 m, adjusted EBITDA of >= € 300 m and unpartnered research and development expenses of > € 100 mGiven current global insecurities surrounding the COVID-19 pandemic, a likely negative impact - though less pronounced than in 2020 - is already estimated within the guidance for revenues and adjusted EBITDA stated above.Key figures of consolidated income statement & segment informationEvotec SE & subsidiaries - First quarter of 2021 In T€ EVT Execute4) EVT Innovate5) Intersegment Eliminations Evotec Group Q1 2021 Evotec Group Q1 2020 External revenues1) 104,880 28,205 - 133,085 119,402 Intersegment revenues 32,033 - (32,033) - - Costs of revenue (107,654) (25,149) 30,397 (102,406) (86,130) Gross profit 29,259 3,056 (1,636) 30,679 33,272 Gross margin in % 21.4 10.8 - 23.1 27.9 R&D expenses2) (2,001) (18,095) 1,636 (18,460) (15,056) SG&A expenses (17,033) (4,161) - (21,194) (17,254) Other operating income (expenses), net 4,587 11,166 - 15,753 15,133 Operating result 14,812 (8,034) - 6,778 16,095 Adjusted EBITDA3) 28,320 (7,215) - 21,105 30,002 1) Adjusted for negative exchange rate effects of € 6.0 m, Group revenues amount to € 139.1 m2) Of which unpartnered R&D expenses of € 14.9 m in Q1 2021 (Q1 2020: € 11.4 m)3) Before changes in contingent considerations, income from bargain purchase and excluding impairments on goodwill, other intangible and tangible assets as well as the total non-operating result4) Revenues from material recharges of € 5.6 m are allocated to EVT Execute as of Q1 20215) Revenues from material recharges of € 0.3 m are allocated to EVT Innovate as of Q1 2021 More detailed information and financial tables are available in our interim statement for the first quarter published on the Evotec website under the following link:https://www.evotec.com/en/invest/financial-publicationsWebcast/Conference CallThe Company is going to hold a conference call to discuss the results of the first quarter 2021 as well as to provide an update on its performance in the reporting period. The conference call will be held in English.Conference call detailsDate: Tuesday, 11 May 2021Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT)From Germany: +49 69 20 17 44 220From France: +33 170 709 502From Italy: +39 023 600 6663From UK: +44 20 3009 2470From USA: +1 877 423 0830Access Code: 94660964#A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20210511/no-audio.Webcast detailsTo join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.The access code is 315614523#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports. ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec. FORWARD LOOKING STATEMENTSInformation set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.IR Contact Evotec SE:Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com 11.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1194778 End of News DGAP News Service

  • EQS Group

    Evotec launches 'beLAB1407' to accelerate translational research from the UK's academic life science ecosystem in collaboration with Bristol Myers Squibb

    DGAP-News: Evotec SE / Key word(s): Miscellaneous06.05.2021 / 07:30 The issuer is solely responsible for the content of this announcement. beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK THE COLLABORATION LEVERAGES EVOTEC'S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATORHamburg, Germany, 06 May 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK's top-tier academic institutions. Through a unique combination of Evotec's drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.Evotec's BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaborations provide an integrated fund and award framework to validate exciting academic projects in collaborations with Pharma and biotech with the goal to form new companies. Since implementing the first academic BRIDGE 'LAB282' in Oxford in November 2016, Evotec has continued to evolve similar collaborations with a variety of academic, Pharma and venture capital partners across Europe and North America.With beLAB1407 representing the continued refinement of the approach, Evotec links one of Europe's foremost academic clusters of excellence in the life sciences with Bristol Myers Squibb as a major biopharmaceutical partner dedicated to advancing innovation in therapeutics from academia to patient benefit. The beLAB1407 collaboration builds on the longstanding and successful relationship between Evotec and Bristol Myers Squibb in drug discovery across several therapeutic areas.Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "We are thrilled to launch beLAB1407 together with our partners at Bristol Myers Squibb with whom we've worked on a variety of projects over a period of many years. beLAB1407 provides researchers from the member institutions with a unique way to fast-track their projects, to validate them on our industrial-grade platform and have partnering options including company formations readily available to them."Dr Thomas Hanke, Head of Academic Partnerships at Evotec, added: "We are delighted to see the BRIDGE concept gaining further traction in the UK and we very much look forward to working closely with our academic partners in the Midlands and Scotland as well as our colleagues at BMS to identify and accelerate the next generation of first-in-class therapeutics across all modalities and therapeutic areas."Dr Rupert Vessey, Executive Vice President and President, Research and Early Development at Bristol Myers Squibb, commented: "This collaboration builds on our important connection to leading European universities. With beLAB1407, we are supporting U.K.-based universities that are exploring many interesting lines of scientific research and discovery. That research combined with Evotec's proprietary data platforms has the potential to identify new and novel therapies for areas of unmet medical need."The name beLAB1407 refers to the distance between Land's End in the far southwest of Great Britain to its north-easternmost point near the village of John o' Groats in Scotland, which - if travelled by bike - adds up to 1,407 kilometres. To learn more about beLAB1407, please visit www.belab1407.org.About Evotec's BRIDGE model: Partnering to accelerate innovationEvotec has created a new paradigm to translate early-stage academic research to drug discovery and development called "BRIDGE" (Biomedical Research, Innovation & Development Generation Efficiency), an integrated fund and award framework to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotech. Through these efforts, Evotec has defined a new formula for fast-track early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded a number of different collaborations, e.g. LAB282, LAB150, LAB031, LAB10x, and Autobahn Labs. Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec's BRIDGEs.Additional quotes:David Coleman, Director Enterprise & Innovation, University of Birmingham Enterprise, commented: "Over the last few years, the University of Birmingham has identified a significant pipeline of early stage life science discoveries. The support and investment provided by Evotec and Bristol Myers Squibb through beLAB1407 provides a great opportunity to validate and develop some of these into important therapies for the future, and we're very excited to be working with them."Dr George Baxter, Chief Executive of Edinburgh Innovations, said: "This innovative collaboration represents the best of academic and industry collaboration. We are delighted to be playing our part in such a high calibre project supporting early stage research become reality. The University of Edinburgh already has an impressive track record of drug discovery supported by our world class facilities. This innovative approach gives us even more opportunity to make our ideas work for a better world."Dr Andrew Naylor, CEO Nottingham Technology Ventures from the University of Nottingham, said: "beLAB1407 is an innovative model for funding early stage drug discovery projects. It encapsulates a collaboration across four leading UK Universities and two highly reputable commercial partners that will provide insight and skills as well as funding. This presents an opportunity for the university to accelerate its drug discovery research and fast track the process of the creation of spin out companies to commercialise the research to benefit society. The university already has a strong track record of developing successful spin-out companies with a portfolio of 25 companies and notable successful examples in Life Sciences include Scancell Plc, Oncimmune Plc, and Exonate Ltd. This collaboration with Evotec and Bristol Myers Squib will only strengthen that further."Dr David McBeth, Director of Research and Innovation Services at the the University of Dundee, said: "beLAB1407 is an initiative that will allow creative institutions like the University of Dundee to capitalise on the ground-breaking research that is carried out here every day. The University is proud to champion a culture of entrepreneurship, and we already have an enviable track record in producing successful spin-out companies. Working as part of beLAB1407 will further allow ourselves and our partner institutions to accelerate the drug discovery breakthroughs that we make, a move that could ultimately transform outcomes for many patients."ABOUT BRISTOL-MYERS SQUIBB COMPANYBristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com/gb or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.FORWARD-LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.Media Contact Evotec SE:Gabriele Hansen, SVP Head of Global Corporate Communications & Marketing, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.comIR Contact Evotec SE:Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, volker.braun@evotec.com06.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1193117 End of News DGAP News Service

  • EQS Group

    Evotec SE to announce results for the first quarter 2021 on 11 May 2021

    DGAP-News: Evotec SE / Key word(s): Miscellaneous04.05.2021 / 11:30 The issuer is solely responsible for the content of this announcement.Hamburg, Germany, 04 May 2021:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first quarter of 2021 on Tuesday, 11 May 2021.The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English.Conference call detailsDate: Tuesday, 11 May 2021Time: 02.00 pm CET (08.00 am EST, 01.00 pm GMT)From Germany: +49 69 20 17 44 220From France: +33 170 709 502From Italy: +39 023 600 6663From UK: +44 20 3009 2470From USA: +1 877 423 0830Access Code: 94660964#A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20210511/no-audio.Webcast detailsTo join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.A replay of the conference call will be available for seven days and can be accessed from Germany by dialling +49 69 201744221, from UK by dialling +44 20 3364 5150 and from USA by dialling +1 (844) 307-9362.The access code is 315614523#. The on-demand version of the webcast will be available on our website: https://www.evotec.com/financial-reports.ABOUT EVOTEC SEEvotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,700 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of more than 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter @Evotec.FORWARD-LOOKING STATEMENTS Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.04.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Evotec SE Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1192318 End of News DGAP News Service